Appendix A. Drug Characteristics Tables

Updated September 25, 2025 Reviewed September 25, 2025

To view a table, please click on the corresponding link:

Table 1. Coformulated and Copackaged Antiretroviral Regimens
Table 2. Nucleoside Reverse Transcriptase Inhibitor-Based, Fixed-Dose Combination Tablets for Use as Part of an Antiretroviral Regimen
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors
Table 4. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors
Table 5. Characteristics of Protease Inhibitors
Table 6. Characteristics of Integrase Strand Transfer Inhibitors
Table 7. Characteristics of the CCR5 Antagonist
Table 8. Characteristics of the CD4 Post-Attachment Inhibitor
Table 9. Characteristics of the gp120 Attachment Inhibitor
Table 10. Characteristics of the Capsid Inhibitor

Appendix A, Table 1. Coformulated and Copackaged Antiretroviral Regimens

Updated: September 12, 2024
Reviewed: September 25, 2025

The following table includes dose recommendations for U.S. Food and Drug Administration (FDA)–approved coformulated and copackaged antiretroviral regimens for adults with HIV. Not all products are FDA approved for adolescents with HIV. For information regarding the use of these medications in adolescents with HIV, including weight limitations and additional dosage forms, please consult FDA product labeling or Appendix A in the Pediatric Antiretroviral Guidelines. Please see the class-specific drug characteristics tables (Appendix A, Tables 3, 4, 5, and 6) for details about the individual drugs included in these products, including information on elimination and metabolic pathways, serum and intracellular half-lives, and adverse effects. The products in this table are listed by drug class and arranged in alphabetical order by generic name within each class.

Generic Name (Abbreviation) Trade Name	ARV Drugs Included in the Regimen	Dosing Recommendation^a
INSTI Plus Two NRTIs
Bictegravir/Tenofovir Alafenamide/Emtricitabine (BIC/TAF/FTC) Biktarvy	BIC 50 mg/TAF 25 mg/FTC 200 mg	One tablet PO once daily
Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Triumeq	DTG 50 mg/ABC 600 mg/3TC 300 mg	One tablet PO once daily
Elvitegravir/Cobicistat/Tenofovir Alafenamide/Emtricitabine (EVG/c/TAF/FTC) Genvoya	EVG 150 mg/COBI 150 mg/TAF 10 mg/FTC 200 mg	One tablet PO once daily with food
Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine (EVG/c/TDF/FTC) Stribild	EVG 150 mg/COBI 150 mg/TDF 300 mg/FTC 200 mg	One tablet PO once daily with food
INSTI Plus One NRTI
Dolutegravir/Lamivudine (DTG/3TC) Dovato	DTG 50 mg/3TC 300 mg	One tablet PO once daily
INSTI Plus One NNRTI
Cabotegravir/Rilpivirine (CAB/RPV) Cabenuva	Cabenuva 600-mg/900-mg Kit: CAB 600-mg/3-mL vial and RPV 900-mg/3-mL vial Cabenuva 400-mg/600-mg Kit: CAB 400-mg/2-mL vial and RPV 600-mg/2-mL vial	Optional Lead-In With Oral CAB and RPV CAB 30 mg PO and RPV 25 mg PO once daily with food for 4 weeks Monthly IM CAB and RPV Loading dose: CAB 600 mg/3 mL IM for 1 dose and RPV 900 mg/‌3 mL IM for 1 dose Continuation phase: CAB 400 mg/2 mL IM every 4 weeks and RPV 600 mg/2 mL IM every 4 weeks Every 2-Month IM CAB and RPV Loading dose: CAB 600 mg/3 mL IM and RPV 900 mg/3 mL IM once monthly for 2 doses Continuation phase: CAB 600 mg/3 mL IM and RPV 900 mg/3 mL IM every 2 months
Dolutegravir/Rilpivirine (DTG/RPV) Juluca	DTG 50 mg/RPV 25 mg	One tablet PO once daily with food
NNRTI Plus Two NRTIs
Doravirine/Tenofovir Disoproxil Fumarate/Lamivudine (DOR/TDF/3TC) Delstrigo	DOR 100 mg/TDF 300 mg/3TC 300 mg	One tablet PO once daily
Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine (EFV/TDF/FTC) Generic Only	EFV 600 mg/TDF 300 mg/FTC 200 mg	One tablet PO once daily on an empty stomach, preferably at bedtime
Efavirenz/Tenofovir Disoproxil Fumarate/Lamivudine (EFV/TDF/3TC) Symfi	EFV 600 mg/TDF 300 mg/3TC 300 mg	One tablet PO once daily on an empty stomach, preferably at bedtime
Rilpivirine/Tenofovir Alafenamide/Emtricitabine (RPV/TAF/FTC) Odefsey	RPV 25 mg/TAF 25 mg/FTC 200 mg	One tablet PO once daily with food
Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) Complera	RPV 25 mg/TDF 300 mg/FTC 200 mg	One tablet PO once daily with food
PI Plus Two NRTIs
Darunavir/Cobicistat/Tenofovir Alafenamide/Emtricitabine (DRV/c/TAF/FTC) Symtuza	DRV 800 mg/COBI 150 mg/TAF 10 mg/FTC 200 mg	One tablet PO once daily with food
^a For dose adjustments in people with renal or hepatic insufficiency, see Appendix B. When no food restriction is listed, the product can be taken with or without food. Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; BIC = bictegravir; c or COBI = cobicistat; CAB = cabotegravir; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; IM = intramuscularly; INSTI = integrase strand transfer inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PO = orally; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate

Appendix A, Table 2. Nucleoside Reverse Transcriptase Inhibitor–Based, Fixed-Dose Combination Tablets for Use as Part of an Antiretroviral Regimen

Updated: September 25, 2025
Reviewed: September 25, 2025

The following table includes dose recommendations for U.S. Food and Drug Administration (FDA)–approved dual nucleoside reverse transcriptase inhibitor fixed-dose combination (FDC) products for adults with HIV. For information regarding the use of these medications in adolescents with HIV, including weight limitations and additional dosage forms, please consult FDA product labeling or Appendix A in the Pediatric Antiretroviral Guidelines. These FDC tablets are not complete regimens and must be administered in combination with other antiretroviral drugs. FDC products that contain zidovudine (ZDV) have been removed from this table. Please refer to the FDA product labels for information regarding ZDV-containing FDCs. Please see the class-specific drug characteristics tables (Appendix A, Tables 3, 4, 5, and 6) for details about the individual drugs contained in these FDC products, including information on elimination and metabolic pathways, serum and intracellular half-lives, and adverse effects. The FDC tablets in this table are listed by generic name.

Generic Name (Abbreviation) Trade Name	ARV Drugs Included in the FDC Tablet	Dosing Recommendation^a
Abacavir/Lamivudine (ABC/3TC) Generic Only	ABC 600 mg/3TC 300 mg	One tablet PO once daily
Tenofovir Alafenamide/Emtricitabine (TAF/FTC) Descovy	TAF 25 mg/FTC 200 mg	One tablet PO once daily
Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) Truvada Note: Generic product available	TDF 300 mg/FTC 200 mg	One tablet PO once daily
Tenofovir Disoproxil Fumarate/Lamivudine (TDF/3TC) Cimduo	TDF 300 mg/3TC 300 mg	One tablet PO once daily
^a For dose adjustments in people with renal or hepatic insufficiency, see Appendix B. All FDC tablets listed in this table can be taken without regard to food. Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; FDC = fixed-dose combination; FTC = emtricitabine; NRTI = nucleoside reverse transcriptase inhibitor; PO = orally; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate

Appendix A, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors

Updated: September 25, 2025
Reviewed: September 25, 2025

The following table includes dose recommendations for U.S. Food and Drug Administration (FDA)–approved nucleoside reverse transcriptase inhibitor products for adults with HIV. For information regarding the use of these medications in adolescents with HIV, including weight limitations and additional dosage forms, please consult FDA product labeling or Appendix A in the Pediatric Antiretroviral Guidelines. The older nucleoside reverse transcriptase inhibitors didanosine (ddI) and stavudine (d4T) have been discontinued in the United States. Zidovudine (ZDV) is no longer used commonly in clinical practice. Therefore, these antiretrovirals have been removed from this table. Please refer to the FDA product label for ZDV for information regarding this drug.

View full version of Appendix A, Table 3.

Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors

Appendix A, Table 4. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors

Updated: September 25, 2025
Reviewed: September 25, 2025

The following table includes dose recommendations for U.S. Food and Drug Administration (FDA)–approved non-nucleoside reverse transcriptase inhibitor (NNRTI) products for adults with HIV. For information regarding the use of these medications in adolescents with HIV, including weight limitations and additional dosage forms, please consult FDA product labeling or Appendix A in the Pediatric Antiretroviral Guidelines. The older NNRTIs delavirdine (DLV) and nevirapine (NVP) are not listed in this table; DLV has been discontinued and NVP is no longer commonly used in clinical practice in the United States.

View full version of Appendix A, Table 4.

Table 4. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Appendix A, Table 5. Characteristics of Protease Inhibitors

Updated: September 25, 2025
Reviewed: September 25, 2025

The following table includes dose recommendations for U.S. Food and Drug Administration (FDA)–approved protease inhibitor products for adults with HIV. For information regarding the use of these medications in adolescents with HIV, including weight limitations and additional dosage forms, please consult FDA product labeling or Appendix A in the Pediatric Antiretroviral Guidelines. The older protease inhibitors indinavir (IDV) and saquinavir (SQV) have been discontinued in the United States; fosamprenavir (FPV), lopinavir/ritonavir (LPV/r), nelfinavir (NFV), and tipranavir (TPV) are no longer used commonly in clinical practice. These agents have been removed from this table. Please refer to the July 10, 2019, version of the guidelines (found in the Adult and Adolescent Antiretroviral Archived Guidelines section of the Archived Guidelines webpage on the Clinicalinfo website) or to the FDA product labels for information regarding these drugs.

View full version of Appendix A, Table 5.

Table 5. Characteristics of Protease Inhibitors

Appendix A, Table 6. Characteristics of Integrase Strand Transfer Inhibitors

Updated: September 12, 2024
Reviewed: September 25, 2025

The following table includes dose recommendations for U.S. Food and Drug Administration (FDA)–approved integrase strand transfer inhibitor products for adults with HIV. Not all formulations are FDA approved for adolescents with HIV. For information regarding the use of these medications in adolescents with HIV, including weight limitations and additional dosage forms, please consult FDA product labeling or Appendix A in the Pediatric Antiretroviral Guidelines.

Generic Name (Abbreviation) Trade Name	Formulations	Dosing Recommendations^a	Elimination/ Metabolic Pathways	Serum Half-Life	Adverse Events^b
Bictegravir (BIC)	BIC is available only as a component of the STR Biktarvy (BIC/TAF/FTC).^c	One tablet PO once daily	CYP3A4 substrate UGT1A1-mediated glucuronidation	~17 hours	Diarrhea Nausea Headache Weight gain
Cabotegravir (CAB)	Available as part of the copackaged IM long-acting regimen Cabenuva (CAB IM and RPV IM) 400-mg/2-mL vial 600-mg/3-mL vial Also available in oral tablet formulation Vocabria (CAB PO) 30-mg tablet Must be obtained from manufacturer for oral lead-in and oral bridging during administration of Cabenuva (CAB IM/RPV IM)	See Appendix A, Table 1 for dosing information for coformulated and copackaged regimens that contain CAB.	UGT1A1 and UGT1A9-mediated glucuronidation	PO: 41 hours IM: 6–12 weeks	CAB Plus RPV Headache Nausea Abnormal dreams Anxiety Insomnia Depressive disorders Hepatotoxicity IM Foundation Only Injection site reactions (e.g., pain, induration, swelling, nodules)
Dolutegravir (DTG) Tivicay	Tivicay 50-mg tablet STRs that Contain DTG^c Dovato (DTG/3TC) Juluca (DTG/RPV) Triumeq (DTG/ABC/3TC)	In People Without Prior ARV Treatment or ARV-Experienced People Who Had Never Received INSTIs DTG 50 mg PO once daily In People Without Prior ARV Treatment or ARV-Experienced People Who Had Never Received INSTIs When Coadministered With EFV, FPV/r, TPV/r, or Rifampin DTG 50 PO mg twice daily In INSTI-Experienced People With Certain INSTI Mutations (See Product Label) or With Clinically Suspected INSTI Resistance DTG 50 mg PO twice daily See Appendix A, Table 1 for dosing information for STRs that contain DTG.	UGT1A1-mediated glucuronidation Minor substrate of CYP3A4	~14 hours	Insomnia Headache Depression disorders and suicidal ideation (rare; usually occurs in people with preexisting psychiatric conditions) Weight gain Hepatotoxicity HSRs, including rash, constitutional symptoms, and organ dysfunction (including liver injury), have been reported.
Elvitegravir (EVG)	EVG is only available as a component of an STR tablet that also contains COBI, FTC, and either TDF or TAF. STRs That Contain EVG^c Genvoya (EVG/c/TAF/FTC) Stribild (EVG/c/TDF/FTC)	Genvoya One tablet PO once daily with food. See Appendix B for recommendations on dosing in persons with renal insufficiency. Stribild One tablet PO once daily with food. Not recommended for people with baseline CrCl <70 mL/min (see Appendix B for the CrCl calculation equation).	EVG CYP3A and UGT1A1/3 substrate COBI CYP3A inhibitor and substrate CYP2D6 inhibitor	EVG/c: ~13 hours	Nausea Diarrhea Depression and suicidal ideation (rare; usually occurs in people with preexisting psychiatric conditions)
Raltegravir (RAL) Isentress Isentress HD	Isentress 400-mg tablet 100-mg single-use packet for oral suspension Isentress HD 600-mg tablet	Isentress 400 mg PO twice daily With Rifampin 800 mg PO twice daily Isentress HD In People Without Prior ARV Treatment or ARV-Experienced People With Virologic Suppression on a Regimen Containing RAL 400 mg Twice Daily 1,200 mg (two 600-mg tablets) PO once daily With Rifampin Not recommended	UGT1A1-mediated glucuronidation	~9 hours	Rash, including Stevens-Johnson syndrome, HSR, and toxic epidermal necrolysis Nausea Headache Diarrhea Pyrexia CPK elevation, muscle weakness, and rhabdomyolysis Weight gain Insomnia Depression and suicidal ideation (rare; usually occurs in people with preexisting psychiatric conditions)
^a For dose adjustments in people with hepatic insufficiency, see Appendix B. When no food restriction is listed, the antiretroviral drug can be taken with or without food. ^b Also see Table 21. ^c See Appendix A, Table 1 for information about these formulations. Key: 3TC = lamivudine; ABC = abacavir; AE = adverse event; ARV = antiretroviral; BIC = bictegravir; CAB = cabotegravir; COBI == cobicistat; CPK = creatine phosphokinase; CrCl = creatinine clearance; CYP = cytochrome P; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FPV/r = fosamprenavir/ritonavir; FTC = emtricitabine; HSR = hypersensitivity reaction; IM = intramuscular; INSTI = integrase strand transfer inhibitor; NTD = neural tube defect; PO = orally; RAL = raltegravir; RPV = rilpivirine; STR = single-tablet regimen; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TPV/r = tipranavir/ritonavir; UGT1 = uridine diphosphate glucuronyl transferase 1 family

Appendix A, Table 7. Characteristics of the CCR5 Antagonist

Updated: September 25, 2025
Reviewed: September 25, 2025

The following table includes dose recommendations for the U.S. Food and Drug Administration (FDA)–approved CCR5 antagonist. For additional information regarding the use of this medication in adolescents with HIV, please consult FDA product labeling or Appendix A in the Pediatric Antiretroviral Guidelines.

Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendation^a	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events^b
Maraviroc (MVC) Selzentry Note: Generic products are available.	Selzentry 150-mg and 300 mg tablets 20-mg/1-mL oral solution Generic 150-mg and 300 mg tablets	MVC 150 mg PO twice daily when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers), including PIs (except TPV/r) MVC 300 mg PO twice daily when given with NRTIs, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers MVC 600 mg PO twice daily when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor) Take MVC without regard to food.	14–18 hours	CYP3A4 substrate	Abdominal pain Cough Dizziness Musculoskeletal symptoms Pyrexia Rash Upper respiratory tract infections Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions Orthostatic hypotension, especially in people with severe renal insufficiency
^a For dose adjustments in people with hepatic insufficiency, see Appendix B. ^b Also see Table 21. Key: CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PO = orally; RAL = raltegravir; TPV/r = tipranavir/ritonavir

Generic Name
(Abbreviation)
Trade Name

Formulation

Dosing Recommendation^a

Serum Half-Life

Elimination/ Metabolic Pathway

Adverse Events^b

Maraviroc
(MVC)
Selzentry

Note: Generic products are available.

Selzentry

150-mg and 300 mg tablets
20-mg/1-mL oral solution

Generic

150-mg and 300 mg tablets

MVC 150 mg PO twice daily when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers), including PIs (except TPV/r)
MVC 300 mg PO twice daily when given with NRTIs, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers
MVC 600 mg PO twice daily when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor)

Take MVC without regard to food.

14–18 hours

CYP3A4 substrate

Abdominal pain

Cough

Dizziness

Musculoskeletal symptoms

Pyrexia

Rash

Upper respiratory tract infections

Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions

Orthostatic hypotension, especially in people with severe renal insufficiency

^a For dose adjustments in people with hepatic insufficiency, see Appendix B.

^b Also see Table 21.

Key: CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PO = orally; RAL = raltegravir; TPV/r = tipranavir/ritonavir

Appendix A, Table 8. Characteristics of the CD4 Post-Attachment Inhibitor

Updated: May 26, 2023
Reviewed: September 25, 2025

The following table includes dose recommendations for the U.S. Food and Drug Administration (FDA)–approved CD4 post-attachment inhibitor. Ibalizumab is not FDA approved for use in adolescents with HIV.

Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events^a
Ibalizumab (IBA) Trogarzo	Single-dose 2‑mL vial containing 200 mg/1.33 mL (150 mg/mL) of ibalizumab	Administer a single loading dose of IBA 2,000-mg IV infusion over 30 minutes, followed by a maintenance dose of IBA 800-mg IV infusion over 15 minutes or IV push over 30 seconds every 2 weeks. See prescribing information for additional instructions for preparing, storing, and administering IBA, and for monitoring people who are receiving IBA.	~64 hours	Not well defined	Diarrhea Dizziness Nausea Rash HSRs, including anaphylaxis and infusion-related reactions, have been reported.
^a Also see Table 21. Key: HSR = hypersensitivity reaction; IBA = ibalizumab; IV = intravenous

Generic Name
(Abbreviation)
Trade Name

Formulation

Dosing Recommendations

Serum Half-Life

Elimination/ Metabolic Pathway

Adverse Events^a

Ibalizumab
(IBA)
Trogarzo

Single-dose 2‑mL vial containing 200 mg/1.33 mL (150 mg/mL) of ibalizumab

Administer a single loading dose of IBA 2,000-mg IV infusion over 30 minutes, followed by a maintenance dose of IBA 800-mg IV infusion over 15 minutes or IV push over 30 seconds every 2 weeks.
See prescribing information for additional instructions for preparing, storing, and administering IBA, and for monitoring people who are receiving IBA.

~64 hours

Not well defined

Diarrhea

Dizziness

Nausea

Rash

HSRs, including anaphylaxis and infusion-related reactions, have been reported.

^a Also see Table 21.

Key: HSR = hypersensitivity reaction; IBA = ibalizumab; IV = intravenous

Appendix A, Table 9. Characteristics of the gp120 Attachment Inhibitor

Updated: May 26, 2023
Reviewed: September 25, 2025

The following table includes dose recommendations for the U.S. Food and Drug Administration (FDA)–approved gp120 attachment inhibitor. Fostemsavir is not FDA approved for use in adolescents with HIV.

Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events^a
Fostemsavir (FTR) Rukobia	600-mg extended-release tablets	FTR 600 mg PO twice daily	11 hours	Hydrolysis (esterases), CYP3A4	Nausea Transaminase elevation; transient bilirubin elevation Sleep disturbance, dizziness QTc prolongation was seen at four times the recommended dose. Use with caution in people with preexisting heart disease, QTc prolongation, or concomitant use of medications that may prolong QTc interval.
^a Also see Table 21. Key: CYP = cytochrome P; FTR = fostemsavir; PO = orally; QTc = corrected QT interval

Generic Name
(Abbreviation)
Trade Name

Formulation

Dosing Recommendations

Serum Half-Life

Elimination/ Metabolic Pathway

Adverse Events^a

Fostemsavir
(FTR)
Rukobia

600-mg extended-release tablets

FTR 600 mg PO twice daily

11 hours

Hydrolysis (esterases), CYP3A4

Nausea

Transaminase elevation; transient bilirubin elevation

Sleep disturbance, dizziness

QTc prolongation was seen at four times the recommended dose. Use with caution in people with preexisting heart disease, QTc prolongation, or concomitant use of medications that may prolong QTc interval.

^a Also see Table 21.

Key: CYP = cytochrome P; FTR = fostemsavir; PO = orally; QTc = corrected QT interval

Appendix A, Table 10. Characteristics of the Capsid Inhibitor

Updated: September 25, 2025
Reviewed: September 25, 2025

The following table includes dose recommendations for the U.S. Food and Drug Administration (FDA)–approved capsid inhibitor. Lenacapavir is not FDA approved for use in adolescents with HIV.

Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events
Lenacapavir (LEN) Sunlenca	300-mg tablet Single-dose 463.5-‍mg/‌‌‌‌‍‌‌‍‌1.5-‍mL vial for injection	Initiation Option 1 Day 1: 927 mg SQ x 1 dose + 600 mg PO x 1 dose Day 2: 600 mg PO x 1 dose Initiation Option 2 Day 1: 600 mg PO x 1 dose Day 2: 600 mg PO x 1 dose Day 8: 300 mg PO x 1 dose Day 15: 927 mg SQ x 1 dose Maintenance Dosing 927 mg by SQ injection every 6 months from the date of the last injection (+/-2 weeks) Note: Each SQ dose requires two injections.	PO: 10–12 days SQ: 8–12 weeks	Substrate of P-‍glycoprotein, CYP3A (minor), UGT1A1 (minor) CYP3A4 inhibitor (moderate)	Injection site reactions, including nodules, induration, and necrosis Serious injection site reactions (e.g., necrosis and ulcer) may occur when LEN is improperly administered intradermally instead of subcutaneously. Nausea, diarrhea, headache
^a Also see Table 21. Key: CYP = cytochrome P; LEN = lenacapavir; PO = orally; SQ = subcutaneous

Generic Name
(Abbreviation)
Trade Name

Formulation

Dosing Recommendations

Serum Half-Life

Elimination/ Metabolic Pathway

Adverse Events

Lenacapavir
(LEN)
Sunlenca

300-mg tablet
Single-dose 463.5-‍mg/‌‌‌‌‍‌‌‍‌1.5-‍mL vial for injection

Initiation Option 1

Day 1: 927 mg SQ x 1 dose + 600 mg PO x 1 dose
Day 2: 600 mg PO x 1 dose

Initiation Option 2

Day 1: 600 mg PO x 1 dose
Day 2: 600 mg PO x 1 dose
Day 8: 300 mg PO x 1 dose
Day 15: 927 mg SQ x 1 dose

Maintenance Dosing

927 mg by SQ injection every 6 months from the date of the last injection (+/-2 weeks)
Note: Each SQ dose requires two injections.

PO: 10–12 days

SQ: 8–12 weeks

Substrate of P-‍glycoprotein, CYP3A (minor), UGT1A1 (minor)

CYP3A4 inhibitor (moderate)

Injection site reactions, including nodules, induration, and necrosis

Serious injection site reactions (e.g., necrosis and ulcer) may occur when LEN is improperly administered intradermally instead of subcutaneously.

Nausea, diarrhea, headache

^a Also see Table 21.

Key: CYP = cytochrome P; LEN = lenacapavir; PO = orally; SQ = subcutaneous

References

Bohjanen P, Johnson M, Szczech L, et al. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother. 2002;46(8):2387-2392. Available at: https://pubmed.ncbi.nlm.nih.gov/12121909.
Fischetti B, Shah K, Taft D, Berkowitz L, Bakshi A, Cha A. Real-world experience with higher-than-recommended doses of lamivudine in patients with varying degrees of renal impairment. Open Forum Infect Di 2018;5(10):ofy225. Available at: https://pubmed.ncbi.nlm.nih.gov/30302352.
Michienzi S, Schriever C, Badowski M. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. Int J STD AIDS. 2019;30(2):181-187. Available at: https://pubmed.ncbi.nlm.nih.gov/30381029.
Wood B, Pozniak A. Dosing lamivudine or emtricitabine in renal impairment: new data confirm it's time for updated guidance! AID 2021;35(8):1305-1307. Available at: https://pubmed.ncbi.nlm.nih.gov/34076616.
Lucas G, Ross M, Stock P, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(9):e96-e138. Available at: https://academic.oup.com/cid/article/59/9/e96/422813.

To view a table, please click on the corresponding link:

Table 1. Coformulated and Copackaged Antiretroviral Regimens
Table 2. Nucleoside Reverse Transcriptase Inhibitor-Based, Fixed-Dose Combination Tablets for Use as Part of an Antiretroviral Regimen
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors
Table 4. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors
Table 5. Characteristics of Protease Inhibitors
Table 6. Characteristics of Integrase Strand Transfer Inhibitors
Table 7. Characteristics of the CCR5 Antagonist
Table 8. Characteristics of the CD4 Post-Attachment Inhibitor
Table 9. Characteristics of the gp120 Attachment Inhibitor
Table 10. Characteristics of the Capsid Inhibitor

Appendix A, Table 1. Coformulated and Copackaged Antiretroviral Regimens

Updated: September 12, 2024
Reviewed: September 25, 2025

Generic Name (Abbreviation) Trade Name	ARV Drugs Included in the Regimen	Dosing Recommendation^a
INSTI Plus Two NRTIs
Bictegravir/Tenofovir Alafenamide/Emtricitabine (BIC/TAF/FTC) Biktarvy	BIC 50 mg/TAF 25 mg/FTC 200 mg	One tablet PO once daily
Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Triumeq	DTG 50 mg/ABC 600 mg/3TC 300 mg	One tablet PO once daily
Elvitegravir/Cobicistat/Tenofovir Alafenamide/Emtricitabine (EVG/c/TAF/FTC) Genvoya	EVG 150 mg/COBI 150 mg/TAF 10 mg/FTC 200 mg	One tablet PO once daily with food
Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine (EVG/c/TDF/FTC) Stribild	EVG 150 mg/COBI 150 mg/TDF 300 mg/FTC 200 mg	One tablet PO once daily with food
INSTI Plus One NRTI
Dolutegravir/Lamivudine (DTG/3TC) Dovato	DTG 50 mg/3TC 300 mg	One tablet PO once daily
INSTI Plus One NNRTI
Cabotegravir/Rilpivirine (CAB/RPV) Cabenuva	Cabenuva 600-mg/900-mg Kit: CAB 600-mg/3-mL vial and RPV 900-mg/3-mL vial Cabenuva 400-mg/600-mg Kit: CAB 400-mg/2-mL vial and RPV 600-mg/2-mL vial	Optional Lead-In With Oral CAB and RPV CAB 30 mg PO and RPV 25 mg PO once daily with food for 4 weeks Monthly IM CAB and RPV Loading dose: CAB 600 mg/3 mL IM for 1 dose and RPV 900 mg/‌3 mL IM for 1 dose Continuation phase: CAB 400 mg/2 mL IM every 4 weeks and RPV 600 mg/2 mL IM every 4 weeks Every 2-Month IM CAB and RPV Loading dose: CAB 600 mg/3 mL IM and RPV 900 mg/3 mL IM once monthly for 2 doses Continuation phase: CAB 600 mg/3 mL IM and RPV 900 mg/3 mL IM every 2 months
Dolutegravir/Rilpivirine (DTG/RPV) Juluca	DTG 50 mg/RPV 25 mg	One tablet PO once daily with food
NNRTI Plus Two NRTIs
Doravirine/Tenofovir Disoproxil Fumarate/Lamivudine (DOR/TDF/3TC) Delstrigo	DOR 100 mg/TDF 300 mg/3TC 300 mg	One tablet PO once daily
Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine (EFV/TDF/FTC) Generic Only	EFV 600 mg/TDF 300 mg/FTC 200 mg	One tablet PO once daily on an empty stomach, preferably at bedtime
Efavirenz/Tenofovir Disoproxil Fumarate/Lamivudine (EFV/TDF/3TC) Symfi	EFV 600 mg/TDF 300 mg/3TC 300 mg	One tablet PO once daily on an empty stomach, preferably at bedtime
Rilpivirine/Tenofovir Alafenamide/Emtricitabine (RPV/TAF/FTC) Odefsey	RPV 25 mg/TAF 25 mg/FTC 200 mg	One tablet PO once daily with food
Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) Complera	RPV 25 mg/TDF 300 mg/FTC 200 mg	One tablet PO once daily with food
PI Plus Two NRTIs
Darunavir/Cobicistat/Tenofovir Alafenamide/Emtricitabine (DRV/c/TAF/FTC) Symtuza	DRV 800 mg/COBI 150 mg/TAF 10 mg/FTC 200 mg	One tablet PO once daily with food
^a For dose adjustments in people with renal or hepatic insufficiency, see Appendix B. When no food restriction is listed, the product can be taken with or without food. Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; BIC = bictegravir; c or COBI = cobicistat; CAB = cabotegravir; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; IM = intramuscularly; INSTI = integrase strand transfer inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PO = orally; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate

Appendix A, Table 2. Nucleoside Reverse Transcriptase Inhibitor–Based, Fixed-Dose Combination Tablets for Use as Part of an Antiretroviral Regimen

Updated: September 25, 2025
Reviewed: September 25, 2025

Generic Name (Abbreviation) Trade Name	ARV Drugs Included in the FDC Tablet	Dosing Recommendation^a
Abacavir/Lamivudine (ABC/3TC) Generic Only	ABC 600 mg/3TC 300 mg	One tablet PO once daily
Tenofovir Alafenamide/Emtricitabine (TAF/FTC) Descovy	TAF 25 mg/FTC 200 mg	One tablet PO once daily
Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) Truvada Note: Generic product available	TDF 300 mg/FTC 200 mg	One tablet PO once daily
Tenofovir Disoproxil Fumarate/Lamivudine (TDF/3TC) Cimduo	TDF 300 mg/3TC 300 mg	One tablet PO once daily
^a For dose adjustments in people with renal or hepatic insufficiency, see Appendix B. All FDC tablets listed in this table can be taken without regard to food. Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; FDC = fixed-dose combination; FTC = emtricitabine; NRTI = nucleoside reverse transcriptase inhibitor; PO = orally; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate

Appendix A, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors

Updated: September 25, 2025
Reviewed: September 25, 2025

View full version of Appendix A, Table 3.

Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors

Appendix A, Table 4. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors

Updated: September 25, 2025
Reviewed: September 25, 2025

View full version of Appendix A, Table 4.

Table 4. Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Appendix A, Table 5. Characteristics of Protease Inhibitors

Updated: September 25, 2025
Reviewed: September 25, 2025

View full version of Appendix A, Table 5.

Table 5. Characteristics of Protease Inhibitors

Appendix A, Table 6. Characteristics of Integrase Strand Transfer Inhibitors

Updated: September 12, 2024
Reviewed: September 25, 2025

Generic Name (Abbreviation) Trade Name	Formulations	Dosing Recommendations^a	Elimination/ Metabolic Pathways	Serum Half-Life	Adverse Events^b
Bictegravir (BIC)	BIC is available only as a component of the STR Biktarvy (BIC/TAF/FTC).^c	One tablet PO once daily	CYP3A4 substrate UGT1A1-mediated glucuronidation	~17 hours	Diarrhea Nausea Headache Weight gain
Cabotegravir (CAB)	Available as part of the copackaged IM long-acting regimen Cabenuva (CAB IM and RPV IM) 400-mg/2-mL vial 600-mg/3-mL vial Also available in oral tablet formulation Vocabria (CAB PO) 30-mg tablet Must be obtained from manufacturer for oral lead-in and oral bridging during administration of Cabenuva (CAB IM/RPV IM)	See Appendix A, Table 1 for dosing information for coformulated and copackaged regimens that contain CAB.	UGT1A1 and UGT1A9-mediated glucuronidation	PO: 41 hours IM: 6–12 weeks	CAB Plus RPV Headache Nausea Abnormal dreams Anxiety Insomnia Depressive disorders Hepatotoxicity IM Foundation Only Injection site reactions (e.g., pain, induration, swelling, nodules)
Dolutegravir (DTG) Tivicay	Tivicay 50-mg tablet STRs that Contain DTG^c Dovato (DTG/3TC) Juluca (DTG/RPV) Triumeq (DTG/ABC/3TC)	In People Without Prior ARV Treatment or ARV-Experienced People Who Had Never Received INSTIs DTG 50 mg PO once daily In People Without Prior ARV Treatment or ARV-Experienced People Who Had Never Received INSTIs When Coadministered With EFV, FPV/r, TPV/r, or Rifampin DTG 50 PO mg twice daily In INSTI-Experienced People With Certain INSTI Mutations (See Product Label) or With Clinically Suspected INSTI Resistance DTG 50 mg PO twice daily See Appendix A, Table 1 for dosing information for STRs that contain DTG.	UGT1A1-mediated glucuronidation Minor substrate of CYP3A4	~14 hours	Insomnia Headache Depression disorders and suicidal ideation (rare; usually occurs in people with preexisting psychiatric conditions) Weight gain Hepatotoxicity HSRs, including rash, constitutional symptoms, and organ dysfunction (including liver injury), have been reported.
Elvitegravir (EVG)	EVG is only available as a component of an STR tablet that also contains COBI, FTC, and either TDF or TAF. STRs That Contain EVG^c Genvoya (EVG/c/TAF/FTC) Stribild (EVG/c/TDF/FTC)	Genvoya One tablet PO once daily with food. See Appendix B for recommendations on dosing in persons with renal insufficiency. Stribild One tablet PO once daily with food. Not recommended for people with baseline CrCl <70 mL/min (see Appendix B for the CrCl calculation equation).	EVG CYP3A and UGT1A1/3 substrate COBI CYP3A inhibitor and substrate CYP2D6 inhibitor	EVG/c: ~13 hours	Nausea Diarrhea Depression and suicidal ideation (rare; usually occurs in people with preexisting psychiatric conditions)
Raltegravir (RAL) Isentress Isentress HD	Isentress 400-mg tablet 100-mg single-use packet for oral suspension Isentress HD 600-mg tablet	Isentress 400 mg PO twice daily With Rifampin 800 mg PO twice daily Isentress HD In People Without Prior ARV Treatment or ARV-Experienced People With Virologic Suppression on a Regimen Containing RAL 400 mg Twice Daily 1,200 mg (two 600-mg tablets) PO once daily With Rifampin Not recommended	UGT1A1-mediated glucuronidation	~9 hours	Rash, including Stevens-Johnson syndrome, HSR, and toxic epidermal necrolysis Nausea Headache Diarrhea Pyrexia CPK elevation, muscle weakness, and rhabdomyolysis Weight gain Insomnia Depression and suicidal ideation (rare; usually occurs in people with preexisting psychiatric conditions)
^a For dose adjustments in people with hepatic insufficiency, see Appendix B. When no food restriction is listed, the antiretroviral drug can be taken with or without food. ^b Also see Table 21. ^c See Appendix A, Table 1 for information about these formulations. Key: 3TC = lamivudine; ABC = abacavir; AE = adverse event; ARV = antiretroviral; BIC = bictegravir; CAB = cabotegravir; COBI == cobicistat; CPK = creatine phosphokinase; CrCl = creatinine clearance; CYP = cytochrome P; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FPV/r = fosamprenavir/ritonavir; FTC = emtricitabine; HSR = hypersensitivity reaction; IM = intramuscular; INSTI = integrase strand transfer inhibitor; NTD = neural tube defect; PO = orally; RAL = raltegravir; RPV = rilpivirine; STR = single-tablet regimen; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TPV/r = tipranavir/ritonavir; UGT1 = uridine diphosphate glucuronyl transferase 1 family

Appendix A, Table 7. Characteristics of the CCR5 Antagonist

Updated: September 25, 2025
Reviewed: September 25, 2025

Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendation^a	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events^b
Maraviroc (MVC) Selzentry Note: Generic products are available.	Selzentry 150-mg and 300 mg tablets 20-mg/1-mL oral solution Generic 150-mg and 300 mg tablets	MVC 150 mg PO twice daily when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers), including PIs (except TPV/r) MVC 300 mg PO twice daily when given with NRTIs, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers MVC 600 mg PO twice daily when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor) Take MVC without regard to food.	14–18 hours	CYP3A4 substrate	Abdominal pain Cough Dizziness Musculoskeletal symptoms Pyrexia Rash Upper respiratory tract infections Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions Orthostatic hypotension, especially in people with severe renal insufficiency
^a For dose adjustments in people with hepatic insufficiency, see Appendix B. ^b Also see Table 21. Key: CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PO = orally; RAL = raltegravir; TPV/r = tipranavir/ritonavir

Generic Name
(Abbreviation)
Trade Name

Formulation

Dosing Recommendation^a

Serum Half-Life

Elimination/ Metabolic Pathway

Adverse Events^b

Maraviroc
(MVC)
Selzentry

Note: Generic products are available.

Selzentry

150-mg and 300 mg tablets
20-mg/1-mL oral solution

Generic

150-mg and 300 mg tablets

MVC 150 mg PO twice daily when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers), including PIs (except TPV/r)
MVC 300 mg PO twice daily when given with NRTIs, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers
MVC 600 mg PO twice daily when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor)

Take MVC without regard to food.

14–18 hours

CYP3A4 substrate

Abdominal pain

Cough

Dizziness

Musculoskeletal symptoms

Pyrexia

Rash

Upper respiratory tract infections

Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions

Orthostatic hypotension, especially in people with severe renal insufficiency

Appendix A, Table 8. Characteristics of the CD4 Post-Attachment Inhibitor

Updated: May 26, 2023
Reviewed: September 25, 2025

Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events^a
Ibalizumab (IBA) Trogarzo	Single-dose 2‑mL vial containing 200 mg/1.33 mL (150 mg/mL) of ibalizumab	Administer a single loading dose of IBA 2,000-mg IV infusion over 30 minutes, followed by a maintenance dose of IBA 800-mg IV infusion over 15 minutes or IV push over 30 seconds every 2 weeks. See prescribing information for additional instructions for preparing, storing, and administering IBA, and for monitoring people who are receiving IBA.	~64 hours	Not well defined	Diarrhea Dizziness Nausea Rash HSRs, including anaphylaxis and infusion-related reactions, have been reported.
^a Also see Table 21. Key: HSR = hypersensitivity reaction; IBA = ibalizumab; IV = intravenous

Generic Name
(Abbreviation)
Trade Name

Formulation

Dosing Recommendations

Serum Half-Life

Elimination/ Metabolic Pathway

Adverse Events^a

Ibalizumab
(IBA)
Trogarzo

Single-dose 2‑mL vial containing 200 mg/1.33 mL (150 mg/mL) of ibalizumab

Administer a single loading dose of IBA 2,000-mg IV infusion over 30 minutes, followed by a maintenance dose of IBA 800-mg IV infusion over 15 minutes or IV push over 30 seconds every 2 weeks.
See prescribing information for additional instructions for preparing, storing, and administering IBA, and for monitoring people who are receiving IBA.

~64 hours

Not well defined

Diarrhea

Dizziness

Nausea

Rash

HSRs, including anaphylaxis and infusion-related reactions, have been reported.

^a Also see Table 21.

Key: HSR = hypersensitivity reaction; IBA = ibalizumab; IV = intravenous

Appendix A, Table 9. Characteristics of the gp120 Attachment Inhibitor

Updated: May 26, 2023
Reviewed: September 25, 2025

Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events^a
Fostemsavir (FTR) Rukobia	600-mg extended-release tablets	FTR 600 mg PO twice daily	11 hours	Hydrolysis (esterases), CYP3A4	Nausea Transaminase elevation; transient bilirubin elevation Sleep disturbance, dizziness QTc prolongation was seen at four times the recommended dose. Use with caution in people with preexisting heart disease, QTc prolongation, or concomitant use of medications that may prolong QTc interval.
^a Also see Table 21. Key: CYP = cytochrome P; FTR = fostemsavir; PO = orally; QTc = corrected QT interval

Generic Name
(Abbreviation)
Trade Name

Formulation

Dosing Recommendations

Serum Half-Life

Elimination/ Metabolic Pathway

Adverse Events^a

Fostemsavir
(FTR)
Rukobia

600-mg extended-release tablets

FTR 600 mg PO twice daily

11 hours

Hydrolysis (esterases), CYP3A4

Nausea

Transaminase elevation; transient bilirubin elevation

Sleep disturbance, dizziness

^a Also see Table 21.

Key: CYP = cytochrome P; FTR = fostemsavir; PO = orally; QTc = corrected QT interval

Appendix A, Table 10. Characteristics of the Capsid Inhibitor

Updated: September 25, 2025
Reviewed: September 25, 2025

Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events
Lenacapavir (LEN) Sunlenca	300-mg tablet Single-dose 463.5-‍mg/‌‌‌‌‍‌‌‍‌1.5-‍mL vial for injection	Initiation Option 1 Day 1: 927 mg SQ x 1 dose + 600 mg PO x 1 dose Day 2: 600 mg PO x 1 dose Initiation Option 2 Day 1: 600 mg PO x 1 dose Day 2: 600 mg PO x 1 dose Day 8: 300 mg PO x 1 dose Day 15: 927 mg SQ x 1 dose Maintenance Dosing 927 mg by SQ injection every 6 months from the date of the last injection (+/-2 weeks) Note: Each SQ dose requires two injections.	PO: 10–12 days SQ: 8–12 weeks	Substrate of P-‍glycoprotein, CYP3A (minor), UGT1A1 (minor) CYP3A4 inhibitor (moderate)	Injection site reactions, including nodules, induration, and necrosis Serious injection site reactions (e.g., necrosis and ulcer) may occur when LEN is improperly administered intradermally instead of subcutaneously. Nausea, diarrhea, headache
^a Also see Table 21. Key: CYP = cytochrome P; LEN = lenacapavir; PO = orally; SQ = subcutaneous

Generic Name
(Abbreviation)
Trade Name

Formulation

Dosing Recommendations

Serum Half-Life

Elimination/ Metabolic Pathway

Adverse Events

Lenacapavir
(LEN)
Sunlenca

300-mg tablet
Single-dose 463.5-‍mg/‌‌‌‌‍‌‌‍‌1.5-‍mL vial for injection

Initiation Option 1

Day 1: 927 mg SQ x 1 dose + 600 mg PO x 1 dose
Day 2: 600 mg PO x 1 dose

Initiation Option 2

Day 1: 600 mg PO x 1 dose
Day 2: 600 mg PO x 1 dose
Day 8: 300 mg PO x 1 dose
Day 15: 927 mg SQ x 1 dose

Maintenance Dosing

927 mg by SQ injection every 6 months from the date of the last injection (+/-2 weeks)
Note: Each SQ dose requires two injections.

PO: 10–12 days

SQ: 8–12 weeks

Substrate of P-‍glycoprotein, CYP3A (minor), UGT1A1 (minor)

CYP3A4 inhibitor (moderate)

Injection site reactions, including nodules, induration, and necrosis

Serious injection site reactions (e.g., necrosis and ulcer) may occur when LEN is improperly administered intradermally instead of subcutaneously.

Nausea, diarrhea, headache

^a Also see Table 21.

Key: CYP = cytochrome P; LEN = lenacapavir; PO = orally; SQ = subcutaneous

Download Guidelines

Section Only PDF (256.48 KB)
Recommendations Only PDF (340.89 KB)
Full Guideline PDF (7.93 MB)
Tables Only PDF (2.87 MB)

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV

Search Guidelines